Pharmaceuticals APAC

APAC In Vivo CAR-T Therapy Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

APAC In Vivo CAR-T Therapy Market Industry Trends and Forecast to 2034: Segmented by (Delivery, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

APAC · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $17.4 Mn Placeholder estimate
Estimate 2025 $26.2 Mn 23.3% of the global market
Projected 2034 $1.06 Bn 3,957% Adds $1.04 Bn over 9 forecast years
CAGR 2025–2034 50.9% Faster than 99% of 183 Pharmaceuticals markets here
Key players 5 Companies profiled
  • APAC is 23.28% of the global market.
  • Among regions, the largest is North America at $49.4 Mn.
  • Fastest growing: Africa at 51.4% a year.
  • APAC ranks 2nd of 6 by size among regions.

Market size projection

APAC

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.04 Bn total, 2026–2034

Year-by-year market size, 2024–2034
In Vivo CAR-T Therapy Market market size by year, APAC
YearMarket sizeChange that yearSince 2025
2024 (estimate) $17.4 Mn — —
2025 (base) $26.2 Mn +$8.8 Mn —
2026 (forecast) $39.5 Mn +$13.3 Mn +50.9%
2027 (forecast) $59.6 Mn +$20.1 Mn +127.7%
2028 (forecast) $90.0 Mn +$30.4 Mn +243.6%
2029 (forecast) $135.8 Mn +$45.8 Mn +418.5%
2030 (forecast) $204.9 Mn +$69.1 Mn +682.4%
2031 (forecast) $309.2 Mn +$104.3 Mn +1,080.7%
2032 (forecast) $466.6 Mn +$157.4 Mn +1,681.7%
2033 (forecast) $704.0 Mn +$237.5 Mn +2,588.5%
2034 (forecast) $1.06 Bn +$358.4 Mn +3,957%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

APAC In Vivo CAR-T Therapy Market Analysis at a glance
Market size, 2025$26.2 Mn placeholder estimate
Forecast, 2034$1.06 Bn placeholder estimate
Growth (CAGR), 2025–203450.9% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDelivery, indication and end user (see all)
Key playersCapstan Therapeutics (AbbVie), Umoja Biopharma, Interius BioTherapeutics, Kelonia Therapeutics, EsoBiotec (AstraZeneca) (see all)
Active clinical trials32 in Asia PacificSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The APAC In Vivo CAR-T Therapy Market Analysis Executive Summary

In vivo CAR-T therapy delivers instructions straight into the body so a patient's own T cells become cancer fighters, without lab manufacturing.

Key segments of the in Vivo CAR-T Therapy market include delivery (Lentiviral Vectors, Lipid Nanoparticles and Targeted Viral Vectors) and indication (Blood Cancers, Autoimmune Diseases and Solid Tumors).

Bar chart: Asia Pacific In Vivo CAR-T Therapy market size, 2024–2034, placeholder estimates. $17.4 Mn in 2024, $26.2 Mn in 2025 and $1.06 Bn in 2034, 50.9% CAGR.
Asia Pacific In Vivo CAR-T Therapy market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

APAC In Vivo CAR-T Therapy Market Dynamics

Market Growth Drivers

Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the in Vivo CAR-T Therapy market.

Opportunity

Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the in Vivo CAR-T Therapy market.

Market Restraints

Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the in Vivo CAR-T Therapy market. Payers are still working out how to pay for one-time cures.

Competitive Landscape for In Vivo CAR-T Therapy Market in APAC

The in Vivo CAR-T Therapy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for In Vivo CAR-T Therapy Market in APAC

In Vivo CAR-T Therapy in APAC: rules, payment and research

In some of the countries we cover here, medicines are approved by TGA (Australia)⁠[1], NMPA (China)⁠[2], Drug Office (Hong Kong)⁠[3], CDSCO (India)⁠[4], PMDA (Japan)⁠[5], NPRA (Malaysia)⁠[6], Medsafe (New Zealand)⁠[7], FDA Philippines (Philippines)⁠[8], HSA (Singapore)⁠[9], Thai FDA (Thailand)⁠[10], BPOM (Indonesia)⁠[11], DRAP (Pakistan)⁠[12], MFDS (South Korea)⁠[13] and Drug Administration of Vietnam (Vietnam)⁠[14]. How care is paid for in some of these countries: Medicare and the PBS (Australia)⁠[15], basic medical insurance (China)⁠[16], the Hospital Authority (Hong Kong)⁠[17], Ayushman Bharat PM-JAY (India)⁠[18], public health insurance (Japan)⁠[19], subsidised public care (Malaysia)⁠[20], Pharmac (New Zealand)⁠[21], PhilHealth (Philippines)⁠[22], MediShield Life (Singapore)⁠[23], the Universal Coverage Scheme (Thailand)⁠[24], JKN (BPJS Kesehatan) (Indonesia)⁠[25], out of pocket and Sehat Sahulat (Pakistan)⁠[26], National Health Insurance (South Korea)⁠[27] and social health insurance (Vietnam)⁠[28]. ClinicalTrials.gov lists 32 studies on In Vivo CAR-T Therapy that are recruiting, active or about to start in APAC.⁠[29]

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] National Medical Products Administration. Checked 14 Nov 2026.

[3] Drug Office, Department of Health. Checked 14 Nov 2026.

[4] Central Drugs Standard Control Organisation. Checked 14 Nov 2026.

[5] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[6] National Pharmaceutical Regulatory Agency. Checked 14 Nov 2026.

[7] Medsafe. Checked 14 Nov 2026.

[8] Food and Drug Administration Philippines. Checked 14 Nov 2026.

[9] Health Sciences Authority. Checked 14 Nov 2026.

[10] Thai Food and Drug Administration. Checked 14 Nov 2026.

[11] National Agency of Drug and Food Control (BPOM). Checked 19 Nov 2026.

[12] Drug Regulatory Authority of Pakistan (DRAP). Checked 19 Nov 2026.

[13] Ministry of Food and Drug Safety. Checked 19 Nov 2026.

[14] Drug Administration of Vietnam. Checked 19 Nov 2026.

[15] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[16] National Healthcare Security Administration. Checked 14 Nov 2026.

[17] Hospital Authority. Checked 14 Nov 2026.

[18] National Health Authority (PM-JAY). Checked 14 Nov 2026.

[19] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[20] Ministry of Health Malaysia. Checked 14 Nov 2026.

[21] Pharmac. Checked 14 Nov 2026.

[22] PhilHealth. Checked 14 Nov 2026.

[23] CPF Board, MediShield Life. Checked 14 Nov 2026.

[24] National Health Security Office. Checked 14 Nov 2026.

[25] BPJS Kesehatan. Checked 19 Nov 2026.

[26] Ministry of National Health Services, Regulations and Coordination. Checked 19 Nov 2026.

[27] Health Insurance Review and Assessment Service (HIRA). Checked 19 Nov 2026.

[28] Vietnam Social Security. Checked 19 Nov 2026.

[29] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for in Vivo CAR-T Therapy. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in APAC.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in In Vivo CAR-T Therapy right now, from free public sources.

Clinical trials

32 active trials in China, India, Japan, South Korea, Australia, Hong Kong, Philippines, Singapore, Thailand, Vietnam, Malaysia, New Zealand, Bangladesh, Afghanistan, Indonesia, Myanmar, Nepal and Pakistan

Recruiting, about to start, or running now. Counted across the 18 countries we report on in APAC.

Top trial sponsors (worldwide)

  1. Chongqing Precision Biotech Co., Ltd 3 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

In Vivo CAR-T Therapy in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the In Vivo CAR-T Therapy market in Asia Pacific?
Placeholder estimate: about $26.2 Mn in 2025, rising to about $1.06 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the In Vivo CAR-T Therapy market in Asia Pacific growing?
Placeholder estimate: about 50.9% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the In Vivo CAR-T Therapy market report cover?
The report splits the market by delivery (Lentiviral Vectors, Lipid Nanoparticles, Targeted Viral Vectors), indication (Blood Cancers, Autoimmune Diseases, Solid Tumors) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the In Vivo CAR-T Therapy market?
Key players include Capstan Therapeutics (AbbVie), Umoja Biopharma, Interius BioTherapeutics, Kelonia Therapeutics and EsoBiotec (AstraZeneca).
What is driving the In Vivo CAR-T Therapy market?
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the in Vivo CAR-T Therapy market.
How many clinical trials on In Vivo CAR-T Therapy are running in Asia Pacific?
32 studies are recruiting, active or about to start in Asia Pacific, counted across the 18 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
How much research is published on In Vivo CAR-T Therapy?
PubMed lists 24 papers on In Vivo CAR-T Therapy added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in APAC

See all

Related on cell and gene therapy and oncology

See the topic